Fulcrum Therapeutics
Small molecules that modulate gene expression to treat genetic diseases
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2015
- Latest Form D
- $68.5M, Jun 2020
- Total capital
- $170M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $170M
- 4 Form D · last Jun 2020
- 77 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 33 pending · first 2019
- Rank in peer group#33 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$68.5M
- Private capital raisedForm D · SEC · 3rd filing$80M
- Private capital raisedForm D · SEC · 2nd filing$5M
- Private capital raisedForm D · SEC · 1st filing$17M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#33 · top 10%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alan EzekowitzDirectorNamed in SEC Form D filings
- Amit HasijaExecutive OfficerNamed in SEC Form D filings
- Bryan StuartExecutive OfficerNamed in SEC Form D filings
- Diego CadavidExecutive OfficerNamed in SEC Form D filings
- James CollinsDirectorNamed in SEC Form D filings
- James GeraghtyDirectorNamed in SEC Form D filings
Show all 12 people
- James TananbaumDirectorNamed in SEC Form D filings
- Kate HavilandDirectorNamed in SEC Form D filings
- Katina DortonDirectorNamed in SEC Form D filings
- Mark LevinDirectorNamed in SEC Form D filings
- Owen WallaceExecutive OfficerNamed in SEC Form D filings
- Robert GouldExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 40- PendingAn Embryonic Ectoderm Development Inhibitor For The Treatment Of Sickle Cell DiseaseUSPTOApplication 18852344
- PendingMacrocyclic Azolopyridine Derivatives As Eed And PRC2 ModulatorsUSPTOApplication 18783250
- PendingMacrocyclic AzolopyridinesUSPTOApplication 18553317
Show all 40 patent records
- An Embryonic Ectoderm Development Inhibitor For The Treatment Of Sickle Cell DiseaseJul 3, 2025 · Application 18852344Pending
- Macrocyclic Azolopyridine Derivatives As Eed And PRC2 ModulatorsJun 19, 2025 · Application 18783250Pending
- Macrocyclic AzolopyridinesNov 7, 2024 · Application 18553317Pending
- Methods Of Treating Facioscapulohumeral Muscular Dystrophy With LosmapimodOct 17, 2024 · Application 18580024Pending
- Macrocyclic Azolopyridine Derivatives As Eed And PRC2 ModulatorsOct 8, 2024 · US 12,109,198Granted
- Methods Of Regulating BCL11A Expression And Treatment Of BCL11A-MEDIATED DisordersJul 18, 2024 · Application 18557694Pending
- Polymorphic Forms Of (S)-12-FLUORO-4-(1-METHYL-1H-PYRAZOL-5-YL)-7A,8,13,14-TETRAHYDRO-7H-[1,2,4]TRIAZOLO[4',3':1,6]PYRIDO[3,2-B]BENZOFURO[4,3-FG][1,4]OXAZONINEJun 20, 2024 · Application 18553352Pending
- Use Of P38 Inhibitors To Reduce Expression Of DUX4Aug 17, 2023 · Application 17949048Pending
- Macrocyclic Azolopyridine Derivatives As Eed And PRC2 ModulatorsFeb 28, 2023 · US 11,590,111Granted
- Use Of P38 Inhibitors To Reduce Expression Of DUX4Oct 25, 2022 · US 11,479,770Granted
- P38 Kinase Inhibitors Reduce DUX4 And Downstream Gene Expression For The Treatment Of FshdSep 8, 2022 · Application 17741993Pending
- P38 Kinase Inhibitors Reduce DUX4 And Downstream Gene Expression For The Treatment Of FshdMay 5, 2022 · Application 17525394Pending
- P38 Kinase Inhibitors Reduce DUX4 And Downstream Gene Expression For The Treatment Of FshdApr 5, 2022 · US 11,291,659Granted
- Compositions And Methods For Increasing Fetal Hemoglobin And Treating Sickle Cell DiseaseJan 20, 2022 · Application 17295782Pending
- Macrocyclic Azolopyridine Derivatives As Eed And PRC2 ModulatorsApr 13, 2021 · US 10,973,805Granted
- P38 Kinase Inhibitors Reduce DUX4 And Downstream Gene Expression For The Treatment Of FshdJan 21, 2020 · US 10,537,560Granted
- P38 Kinase Inhibitors Reduce DUX4 And Downstream Gene Expression For The Treatment Of FshdJul 9, 2019 · US 10,342,786Granted
- Methods Of Treating Glucose Transporter Type 1 Deficiency Syndrome (GLUT1DS)Application PCTUS2022015230Pending
- Methods Of Treating Facioscapulohumeral Muscular Dystrophy With LosmapimodApplication 63203628Pending
- Methods Of Regulating BCL11A Expression And Treatment Of BCL11A-MEDIATED DisordersApplication 63181747Pending
- Macrocyclic AzolopyridinesApplication 63170226Pending
- Macrocyclic AzolopyridinesApplication 63170212Pending
- Use Of Losmapimod For Treatment Of COVID-19Application PCTUS2021023526Pending
- Methods Of Treating Glucose Transporter Type 1 Deficiency Syndrome (GLUT1DS)Application 63145737Pending
- Use Of Losmapimod For Treatment Of COVID-19Application 62993013Pending
- Macrocyclic Azolopyridine Derivatives As Eed And PRC2 ModulatorsApplication PCTUS2020022724Pending
- Compositions And Methods For Increasing Fetal Hemoglobin And Treating Sickle Cell DiseaseApplication PCTUS2019062461Pending
- Macrocyclic Azolopyridine Derivatives As Eed And PRC2 ModulatorsApplication 62819064Pending
- Compositions And Methods For Increasing Fetal Hemoglobin And Treating Sickle Cell DiseaseApplication 62769796Pending
- P38 Kinase Inhibitors Reduce DUX4 And Downstream Gene Expression For The Treatment Of FshdApplication PCTUS2018054642Pending
- Use Of P38 Inhibitors To Reduce Expression Of DUX4Application PCTUS2018054638Pending
- P38 Kinase Inhibitors Reduce DUX4 And Downstream Gene Expression For The Treatment Of FshdApplication 62682565Pending
- Use Of P38 Inhibitors To Reduce Expression Of DUX4Application 62682563Pending
- Compositions And Methods For Increasing FMR1 ExpressionApplication PCTUS2018022681Pending
- Compositions And Methods For Increasing FMR1 ExpressionApplication 62578138Pending
- Use Of P38 Inhibitors To Reduce Expression Of DUX4 And Downstream GenesApplication 62568754Pending
- Use Of P38 Inhibitors For Reducing DUX4 And Downstream Gene ExpressionApplication 62568673Pending
- Antibody Oligonucleotide Conjugates For Treating DiseaseApplication PCTUS2025054619Pending
- Compositions And Methods For Increasing FMR1 ExpressionApplication 62471919Pending
- Improved Calmodulin Inhibitors And Methods Of Use ThereofApplication PCTUS2025047186Pending
Related companies, and why
- Areteia TherapeuticsSimilar federal contract value in Biotech · null in contracts
- TRIANA BiomedicinesSimilar federal contract value in Biotech · null in contracts
- Monocacy Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- Erasca, Inc.Similar federal contract value in Biotech · null in contracts
- Skye BioscienceSimilar federal contract value in Biotech · null in contracts
- LIGHT SWITCH BIO, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .